康希諾(688185.SH)半年度淨利預計為9-10.5億元 實現扭虧為盈
格隆匯7月16日丨康希諾(688185.SH)公吿,經公司財務部門初步測算,預計2021年上半年度實現營業收入20億元到22億元,與上年同期相比,收入增加約19.96億元-約21.96億元,同比增加49,532.59%到54,495.85%。
預計2021年上半年度實現歸屬於母公司所有者的淨利潤為9億元到10.5億元,與上年同期相比,實現扭虧為盈,增加約10.02億元-約11.52億元。
本期業績變化的主要原因:
(一)主營業務影響。報吿期內,公司重組新型冠狀病毒疫苗(5型腺病毒載體)已獲得墨西哥、巴基斯坦等國的緊急使用授權及中國附條件上市批准,對公司的主營業務收入及歸屬於母公司所有者的淨利潤產生積極影響。
(二)非經營性損益的影響。主要為本期閒置資金現金管理收益增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.